MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - TTK HEALTHCARE
ASTRAZENECA PHARMA vs TTK HEALTHCARE - Comparison Results
Current Valuations
| ASTRAZENECA PHARMA | TTK HEALTHCARE | ASTRAZENECA PHARMA/ TTK HEALTHCARE |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 76.0 | 18.3 | 416.3% | View Chart |
| P/BV | x | 21.4 | 1.5 | 1,464.5% | View Chart |
| Dividend Yield | % | 0.0 | 1.1 | - |
Financials
 ASTRAZENECA PHARMA  TTK HEALTHCARE |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
TTK HEALTHCARE Mar-19 |
ASTRAZENECA PHARMA/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,215 | 105.2% | |
| Low | Rs | 883 | 610 | 144.7% | |
| Sales per share (Unadj.) | Rs | 228.4 | 444.4 | 51.4% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 17.2 | 60.1% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 27.6 | 58.9% | |
| Dividends per share (Unadj.) | Rs | 0 | 5.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.5 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 177.9 | 55.5% | |
| Shares outstanding (eoy) | m | 25.00 | 14.13 | 176.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 2.1 | 230.3% | |
| Avg P/E ratio | x | 104.2 | 52.9 | 197.0% | |
| P/CF ratio (eoy) | x | 66.4 | 33.0 | 201.2% | |
| Price / Book Value ratio | x | 10.9 | 5.1 | 213.3% | |
| Dividend payout | % | 0 | 29.0 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 12,894 | 209.5% | |
| No. of employees | `000 | 1.4 | 2.3 | 58.7% | |
| Total wages/salary | Rs m | 1,535 | 1,307 | 117.5% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 2,715.7 | 155.1% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 565.3 | 200.3% | |
| Avg. net profit/employee | Rs Th | 191.1 | 105.4 | 181.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 6,279 | 90.9% | |
| Other income | Rs m | 123 | 78 | 158.1% | |
| Total revenues | Rs m | 5,833 | 6,356 | 91.8% | |
| Gross profit | Rs m | 463 | 496 | 93.4% | |
| Depreciation | Rs m | 147 | 147 | 100.5% | |
| Interest | Rs m | 0 | 34 | 0.0% | |
| Profit before tax | Rs m | 438 | 393 | 111.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 149 | 120.1% | |
| Profit after tax | Rs m | 259 | 244 | 106.3% | |
| Gross profit margin | % | 8.1 | 7.9 | 102.7% | |
| Effective tax rate | % | 40.8 | 37.9 | 107.7% | |
| Net profit margin | % | 4.5 | 3.9 | 116.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 2,717 | 118.1% | |
| Current liabilities | Rs m | 2,070 | 1,571 | 131.7% | |
| Net working cap to sales | % | 20.0 | 18.3 | 109.3% | |
| Current ratio | x | 1.6 | 1.7 | 89.6% | |
| Inventory Days | Days | 72 | 32 | 225.0% | |
| Debtors Days | Days | 35 | 47 | 74.9% | |
| Net fixed assets | Rs m | 790 | 991 | 79.7% | |
| Share capital | Rs m | 50 | 141 | 35.4% | |
| "Free" reserves | Rs m | 2,419 | 2,373 | 102.0% | |
| Net worth | Rs m | 2,469 | 2,514 | 98.2% | |
| Long term debt | Rs m | 0 | 3 | 0.0% | |
| Total assets | Rs m | 4,605 | 4,158 | 110.8% | |
| Interest coverage | x | NM | 12.6 | - | |
| Debt to equity ratio | x | 0 | 0 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 1.5 | 82.1% | |
| Return on assets | % | 5.6 | 6.7 | 84.3% | |
| Return on equity | % | 10.5 | 9.7 | 108.3% | |
| Return on capital | % | 17.7 | 16.9 | 104.7% | |
| Exports to sales | % | 0 | 3.6 | 0.0% | |
| Imports to sales | % | 0 | 0.5 | 0.0% | |
| Exports (fob) | Rs m | NA | 225 | 0.0% | |
| Imports (cif) | Rs m | NA | 31 | 0.0% | |
| Fx inflow | Rs m | 300 | 225 | 133.0% | |
| Fx outflow | Rs m | 2,015 | 71 | 2,833.5% | |
| Net fx | Rs m | -1,715 | 154 | -1,113.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 173 | 50.8% | |
| From Investments | Rs m | -94 | 97 | -97.0% | |
| From Financial Activity | Rs m | NA | -307 | 0.0% | |
| Net Cashflow | Rs m | -6 | -38 | 15.1% | |
Share Holding
| Indian Promoters | % | 0.0 | 65.4 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 3.7 | 8.1% | |
| FIIs | % | 15.7 | 5.2 | 301.9% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 25.8 | 35.3% | |
| Shareholders | 12,856 | 12,723 | 101.0% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: DR. REDDYS LAB IPCA LABS NATCO PHARMA SUN PHARMA PIRAMAL ENTERPRISES
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)
On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.
Related Views on News
TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)
Jul 18, 2019 | Updated on Jul 18, 2019Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.
TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)
Sep 5, 2019Everyone dreams of owning a business. Here is your chance.
7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)
Sep 5, 2019The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?
Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)
Sep 4, 2019Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.
Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)
Sep 3, 2019Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
MoreASTRAZENECA PHARMA SHARE PRICE
Sep 13, 2019 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.